Corgi | $108,000,000 | (Jan 9, 2026)
Corsera Health | $80,000,000 | (Jan 9, 2026)
Oasys | $4,600,000 | (Jan 9, 2026)
Depixus
France
- Paris
- 15/12/2021
- Series A
- $35,400,000
Depixus (formerly PicoSeq) is undertaking commercial development of a disruptive new technology for the fast, accurate, and inexpensive extraction of sequence and epigenetic information from long individual molecules of DNA and RNA.
Our MAGNA technology goes beyond decoding the static genetic code to reveal the dynamics of the genome that control health and disease.
- Industry Biotechnology Research
- Website https://depixus.com/
- LinkedIn https://www.linkedin.com/company/depixus/
Related People
Gordon HamiltonCo Founder
France -
Greater Paris Metropolitan Region
Proven entrepreneur and business executive in the life-sciences sector. Founder of Depixus, a fast-growing Paris-based biotechnology company and The Electives Network, a successful international healthcare education company. Previously worked as Medical Director for ChemoCentryx, a Californian biotechnology company. Studied Physiological Sciences (Medicine) at Oxford University, holds a medical degree from Imperial College London, and an MBA from INSEAD.
Specialties: life-sciences entrepreneurship, genetic & epigenetic analysis, clinical-phase drug development, emergency physician, company founder and director
Vizgen | $48,000,000 | (Jan 9, 2026)
Poplar Therapeutics | $50,000,000 | (Jan 9, 2026)
Carna Health | $8,000,000 | (Jan 9, 2026)
Valinor(US) | $54,000,000 | (Jan 9, 2026)
Alveus Therapeutics Inc | $160,000,000 | (Jan 9, 2026)
AgileRL | $7,500,000 | (Jan 9, 2026)
Soley Therapeutics | $200,000,000 | (Jan 9, 2026)
EpiBiologics | $107,000,000 | (Jan 9, 2026)
SpangleAI | $15,000,000 | (Jan 9, 2026)
Presto Phoenix, Inc. | $10,000,000 | (Jan 9, 2026)